Literature DB >> 16671076

Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study.

Mette Brandt-Christensen1, Kajsa Kvist, Flemming Mørkeberg Nilsson, Per Kragh Andersen, Lars Vedel Kessing.   

Abstract

The objective of the present study was to record the use of antiparkinsonian drugs (APD) in Denmark and discuss estimates of the incidence and prevalence rates of Parkinson's disease (PD). The main indication for treatment with APD is idiopathic PD. The use of APD is, therefore, an indicator of the epidemiology of PD and Parkinsonism. We used a drug tracer design, which previously has been found applicable in estimating the frequency of PD. From a national prescription database, all persons who purchased APD from 1995 to 2002 could be identified on an individual level. Results show an age-standardized prevalence rate for APD purchase of 164.0 persons per 100,000, and an incidence rate of 55.9 persons per 100,000. The total number of persons purchasing APD was 11,656 per year on average. Our results showed higher figures of persons purchasing APD than the estimated prevalence of idiopathic PD in Denmark, which is approximately 100 persons per 100,000, corresponding to 5,000 to 6,000 persons. The differences might in part be explained by other indications for APD prescription in addition to PD and in part by misdiagnosis. However, the possibility of somewhat higher incidence and prevalence rates of PD than hitherto estimated should be considered. (c) 2006 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16671076     DOI: 10.1002/mds.20907

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  4 in total

1.  Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach.

Authors:  O Chillag-Talmor; N Giladi; S Linn; T Gurevich; B El-Ad; B Silverman; N Friedman; C Peretz
Journal:  J Neurol       Date:  2012-07-07       Impact factor: 4.849

2.  Risk of Parkinson's disease after tamoxifen treatment.

Authors:  Jeanne C Latourelle; Merete Dybdahl; Anita L Destefano; Richard H Myers; Timothy L Lash
Journal:  BMC Neurol       Date:  2010-04-12       Impact factor: 2.474

3.  Use of Fall-Risk Inducing Drugs in Patients Using Anti-Parkinson Drugs (APD): A Swedish Register-Based Study.

Authors:  Ylva Haasum; Johan Fastbom; Kristina Johnell
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

4.  Identifying Parkinson's disease and parkinsonism cases using routinely collected healthcare data: A systematic review.

Authors:  Zoe Harding; Tim Wilkinson; Anna Stevenson; Sophie Horrocks; Amanda Ly; Christian Schnier; David P Breen; Kristiina Rannikmäe; Cathie L M Sudlow
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.